Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | SLC6A15 | Q9H2J7 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23460007 | 0.90 | MEN1 (0.57) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL8050780 | 0.88 | MEN1 (0.55) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL27236981 | 0.87 | KMT2A (0.72) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL20572886 | 0.85 | MAOB (0.54) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL30438181 | 0.85 | MEN1 (0.53) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL14013291 | 0.85 | MAPT (0.53) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL8036213 | 0.85 | ALDH1A1 (0.53) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL19900425 | 0.85 | MEN1 (0.53) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL7290713 | 0.84 | CYP24A1 (0.53) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL972021 | 0.84 | CYP24A1 (0.53) | MEN1KMT2AMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148551-B2 | Tricyclic aromatics and liquid-crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-04-03 | — | — | US | disclosed |
| US-20090131689-A1 | TRICYCLIC AROMATICS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2009-05-21 | — | — | US | disclosed |
| WO-2007085297-A1 | TRICYCLIC AROMATICS AND LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2007-08-02 | — | — | WO | disclosed |
| EP-1349830-A1 | TETRALONE DERIVATIVES AS ANTITUMOR AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-6531472-B2 | Has histone deacetylase (HDAC) inhibitory activity which is useful in cancer treatment | HOFFMAN-LA ROCHE INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2002046144-A1 | TETRALONE DERIVATIVES AS ANTITUMOR AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
| US-20020065282-A1 | Tetralone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-30 | — | — | US | disclosed |
| EP-0991772-A1 | METHODS AND PRECURSORS FOR THE PRODUCTION OF CHIRAL VICINAL AMINOALCOHOLS | Biocatalytics, Inc. (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998054350-A1 | METHODS AND PRECURSORS FOR THE PRODUCTION OF CHIRAL VICINAL AMINOALCOHOLS | BIOCATALYTICS, INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131689-A1 | TRICYCLIC AROMATICS AND LIQUID-CRYSTALLINE MEDIUM | CHRM1, C1S, CHRM2 | MEN1 2244/4885KMT2A 3242/4885MAPT 1097/4885 |
| US-20020065282-A1 | Tetralone derivatives | HDAC1, HDAC5, HDAC3 | MEN1 2298/4885KMT2A 150/4885MAPT 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.